Telix Secures FDA Nod for First Brain Cancer Imaging Drug Pixclara
Event summary
- FDA approved Telix’s Pixclara (floretyrosine F 18) for glioma imaging on September 14, 2026.
- Pixclara is the first FDA-approved FET-PET imaging drug for brain cancer.
- The drug is indicated for differentiating recurrent/progressive glioma from treatment-related changes in adults and pediatric patients.
- Telix’s Precision Medicine business expands with this approval, reinforcing its leadership in theranostics.
The big picture
Telix’s FDA approval for Pixclara addresses a significant unmet need in brain cancer diagnostics, aligning with international clinical guidelines. This approval strengthens Telix’s position in the theranostics market, which combines precision diagnostics with targeted therapies. The company’s growing portfolio of radiopharmaceuticals positions it as a key player in the evolving landscape of cancer treatment and imaging.
What we're watching
- Market Penetration
- How quickly Pixclara will be adopted in U.S. clinical practice, given its FDA approval and inclusion in international guidelines.
- Pipeline Progress
- The pace at which Telix advances its other theranostic candidates, particularly TLX101-Tx for glioblastoma.
- Competitive Dynamics
- Whether Telix can sustain its leadership in theranostics amid potential competition in the brain cancer imaging space.
Related topics